ReviewFrontiers in nuclear medicine2026
Meta-analysis of efficacy and safety of Yttrium-90 radioembolization (TARE) in the treatment of advanced hepatocellular carcinoma.
Review in Frontiers in nuclear medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Transarterial radioembolization (TARE) using Yttrium-90 microspheres has emerged as a promising locoregional therapy for patients with advanced hepatocellular carcinoma (HCC). However, the efficacy and safety of TARE compared to conventional treatments remain uncertain. This meta-analysis aimed to comprehensively evaluate the survival outcomes and safety profile of TARE in advanced HCC. Methods: A systematic literature search was conducted in PubMed, Embase, Cochrane Library, and Web of Science up to May 2025, following the PRISMA guidelines. Studies comparing TARE with conventional or systemic therapies in advanced HCC were included. Pooled hazard ratios (HRs) for overall survival (OS) and progression-free survival (PFS), and odds ratios (ORs) for adverse events (AEs) were calculated using random-effects models. Subgroup and meta-regression analyses explored the influence of study design, liver function (Child-Pugh, ALBI grade), and combined therapies. Results: Forty studies encompassing over 10,000 patients were included. TARE significantly improved OS (pooled HR = 0.72, 95% CI 0.63-0.83) and PFS (pooled HR = 0.78, 95% CI 0.69-0.89) compared with controls. Rates of grade ≥3 adverse events were lower in the TARE group (pooled OR = 0.74, 95% CI 0.59-0.93). Subgroup analyses indicated consistent benefits across retrospective and prospective studies, and in patients with Child-Pugh A-B liver function. Meta-regression revealed that younger age and higher objective response rate were associated with improved outcomes. Conclusion: TARE with Yttrium-90 microspheres confers significant survival benefits and acceptable safety in advanced HCC. These findings support the integration of TARE into multidisciplinary management strategies for advanced HCC, particularly in patients unsuitable for surgical or systemic therapies. Systematic Review Registration: PROSPERO (CRD420251163947).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.